Paul E Finke

This inventor holds 51 USPTO granted patents and 2 published patent applications and 4 EPO patents, primarily in Chemokine Receptor Modulators (CPC class 5142). Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., University of Washington. Active years: 1983-2018.

USPTO Granted Patents = 51 (Patent Applications = 2)

% Patents Active = 88.2

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 5.8

ph-index = 14

Forward Citations = 555(Granted Patents)

Forward Citations (Not Self Cited) = 509(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Metuchen, NJ (US) (1983 - 1987)
Milltosn, NJ (US) (1995)
Miltown, NJ (US) (2007)
Milltown, NJ (US) (1987 - 2018)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 2,165

University of Washington

patents

where one patent can have more than one assignee

Years Active: 1983-2018

Loading Chart...

Areas of Expertise:

Chemokine Receptor Modulators

Antidiabetic Compounds

Tachykinin Receptor Antagonists

Spiroxazolidinone Compounds

Morpholine Derivatives

Cyclic Amine Modulators

Substituted Imidazoles

Alicyclic Compounds

Substituted Azetidinones

Neurokinin Antagonists

Inhibitors

Anti-Inflammatory Agents

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10100042 - [5,6]—fused bicyclic antidiabetic compounds (2018-10-16),

2. 9527830 - Inhibitors of the renal outer medullary potassium channel (2016-12-27),

3. 8742110 - Spiroxazolidinone compounds (2014-06-03),

4. 8399507 - Antidiabetic tricyclic compounds (2013-03-19),

5. 8283344 - Method of treating inherited severe neutropenia (2012-10-09),

6. 7572785 - Substituted imidazoles as cannabinoid receptor modulators (2009-08-11),

7. 7271266 - Substituted 2,3-diphenyl pyridines (2007-09-18),

8. 7196113 - Lactam tachykinin receptor antagonists (2007-03-27),

9. 7091211 - Cyclopentyl modulators of chemokine receptor activity (2006-08-15),

10. 7057051 - Substituted imidazoles as cannabinoid receptor modulators (2006-06-06),

11. 6638930 - Morpholine and thiomorpholine tachykinin receptor antagonists (2003-10-28),

12. 6593346 - N-cyclopentyl modulators of chemokine receptor activity (2003-07-15),

13. 6538002 - Cyclopentyl modulators of chemokine receptor activity (2003-03-25),

14. 6506777 - Cyclopentyl modulators of chemokine receptor activity (2003-01-14),

15. 6500844 - Cyclopentyl modulators of chemokine receptor activity (2002-12-31),

Title: The Innovative Journey of Paul E Finke

Introduction: Paul E Finke, a talented inventor hailing from Milltown, NJ, has made significant contributions to the world of innovation with his creative mind and dedication to problem-solving.

Latest Patents: Paul E Finke's latest patents include groundbreaking inventions in the field of renewable energy technology, specifically focusing on solar panel efficiency and energy storage solutions.

Career Highlights: Throughout his illustrious career, Paul E Finke has been recognized for his pioneering work in sustainable technologies, earning multiple awards for his innovative approach to environmental challenges.

Collaborations: Paul E Finke has collaborated with leading research institutions and universities to further develop his inventions, showcasing his ability to work effectively in multidisciplinary teams to bring ideas to life.

Conclusion: Paul E Finke's passion for innovation and commitment to creating a more sustainable future through his inventions truly sets him apart as a visionary inventor in the modern era.